Low Performance of a Clinical-Genetic Model in the Estimation of Time in Therapeutic Range in Acenocoumarol-Adherent Patients with Nonvalvular Atrial Fibrillation: The Quality of Anticoagulation Challenge

Table 2

Proportion of polymorphisms according to time in therapeutic range.

	Total cohort (n=212)	TTR <70 (n=128, 60.4)	TTR ≥70 (n=84, 39.6)	p-value
VKORC ≥ 1 allele T, (TT/CT), n ()	138 (65.1)	85 (66.4)	53 (63.1)	0.621
CYP2C92 ≥1 allele T (TT/CT), n ()	75 (35.4)	44 (34.4)	31 (36.9)	0.706
CYP2C93 ≥ 1 allele C (CC/CA), n ()	35 (16.5)	20 (15.6)	15 (17.9)	0.669
MIR133A2 ≥ 1 allele A (AA/GG), n ()	82 (38.7)	51 (39.8)	31 (36.9)	0.667

TTR, time in therapeutic range.